Skip to main content
Erschienen in: Neurological Sciences 1/2014

01.05.2014 | SESSION IV UNCONVENTIONAL TREATMENTS

Riboflavin and migraine: the bridge over troubled mitochondria

verfasst von: Bruno Colombo, Lorenzo Saraceno, Giancarlo Comi

Erschienen in: Neurological Sciences | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Brain energy metabolism has been found to be disturbed in migraine. A mitochondrial defect may reduce the threshold for migraine attacks both increasing neuronal excitability and leading migrainous brain to a hyper-responsiveness to triggering stimuli. Riboflavin, a major co-factor in oxidative metabolism, may overcome this impairment. RCT studies in adult confirmed that riboflavin is safe and probably effective in migraine prophylaxis, based on level B evidence. Improving brain energy metabolism may reduce the susceptibility to migraine when brain energy demand increases due to both physiological and biopsychological factors.
Literatur
1.
Zurück zum Zitat Ramadan NM (2004) Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 8:91–95PubMedCrossRef Ramadan NM (2004) Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 8:91–95PubMedCrossRef
2.
Zurück zum Zitat Coppola G, Pierelli F, Schoenen J (2007) Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 27:1427–1439PubMedCrossRef Coppola G, Pierelli F, Schoenen J (2007) Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 27:1427–1439PubMedCrossRef
3.
Zurück zum Zitat Stankewitz A, May A (2009) The phenomenon of changes in cortical excitability in migraine is not migraine-specific—a unifying thesis. Pain 145:14–17PubMedCrossRef Stankewitz A, May A (2009) The phenomenon of changes in cortical excitability in migraine is not migraine-specific—a unifying thesis. Pain 145:14–17PubMedCrossRef
4.
Zurück zum Zitat Wallace DC (2001) Mitochondrial defects in neurodegenerative disease. MRDD Res Rev 7:158–166 Wallace DC (2001) Mitochondrial defects in neurodegenerative disease. MRDD Res Rev 7:158–166
5.
Zurück zum Zitat Stuart S, Griffiths LR (2012) A possible role for mitochondrial dysfunction in migraine. Mol Genet Genomics 287:837–844PubMedCrossRef Stuart S, Griffiths LR (2012) A possible role for mitochondrial dysfunction in migraine. Mol Genet Genomics 287:837–844PubMedCrossRef
6.
Zurück zum Zitat Sangiorgi S, Mochi M, Riva R et al (1994) Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 14:21–23PubMedCrossRef Sangiorgi S, Mochi M, Riva R et al (1994) Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 14:21–23PubMedCrossRef
7.
Zurück zum Zitat Shimomura T, Kowa H, Nakano T et al (1994) Platelet superoxide dismutase in migraine and tension-type headache. Cephalalgia 14:215–218PubMedCrossRef Shimomura T, Kowa H, Nakano T et al (1994) Platelet superoxide dismutase in migraine and tension-type headache. Cephalalgia 14:215–218PubMedCrossRef
8.
Zurück zum Zitat Balbi T, Fusco M, Vasapollo D et al (2005) The presence of trace amines in postmortem cerebrospinal fluid in humans. J Forensic Sci 50:630–632PubMedCrossRef Balbi T, Fusco M, Vasapollo D et al (2005) The presence of trace amines in postmortem cerebrospinal fluid in humans. J Forensic Sci 50:630–632PubMedCrossRef
9.
Zurück zum Zitat Welch KM, Levine SR, D’Andrea G et al (1989) Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39:538–541PubMedCrossRef Welch KM, Levine SR, D’Andrea G et al (1989) Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39:538–541PubMedCrossRef
10.
Zurück zum Zitat Montagna P, Cortelli P, Barbiroli B et al (1994) Magnetic resonance spectroscopy studies in migraine. Cephalalgia 14:184–193PubMedCrossRef Montagna P, Cortelli P, Barbiroli B et al (1994) Magnetic resonance spectroscopy studies in migraine. Cephalalgia 14:184–193PubMedCrossRef
11.
Zurück zum Zitat Antozzi C, Garavaglia B, Mora M et al (1994) Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology 44:2153–2158PubMedCrossRef Antozzi C, Garavaglia B, Mora M et al (1994) Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology 44:2153–2158PubMedCrossRef
12.
Zurück zum Zitat Scholte HR, Busch HF, Bakker HD et al (1995) Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1271:75–83PubMedCrossRef Scholte HR, Busch HF, Bakker HD et al (1995) Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1271:75–83PubMedCrossRef
13.
Zurück zum Zitat Taylor FR (2011) Nutraceuticals and headache: the biological basis. Headache 2011(51):484–501CrossRef Taylor FR (2011) Nutraceuticals and headache: the biological basis. Headache 2011(51):484–501CrossRef
14.
Zurück zum Zitat Smith C (1946) Riboflavin in migraine. CMAJ 54:589–591 Smith C (1946) Riboflavin in migraine. CMAJ 54:589–591
15.
Zurück zum Zitat Schoenen J, Lenaerts M, Bastings E (1994) High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 14:328–329PubMedCrossRef Schoenen J, Lenaerts M, Bastings E (1994) High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 14:328–329PubMedCrossRef
16.
Zurück zum Zitat Boehnke C, Reuter U, Flach U et al (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 11:475–477PubMedCrossRef Boehnke C, Reuter U, Flach U et al (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 11:475–477PubMedCrossRef
17.
Zurück zum Zitat Di Lorenzo C, Pierelli F, Coppola G (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72:1588–1594PubMedCrossRef Di Lorenzo C, Pierelli F, Coppola G (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72:1588–1594PubMedCrossRef
18.
Zurück zum Zitat Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2):466–470PubMedCrossRef Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2):466–470PubMedCrossRef
19.
Zurück zum Zitat Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890PubMedCrossRef Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890PubMedCrossRef
20.
Zurück zum Zitat Holland S, Silberstein SD, Freitag F et al (2012) Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1346–1353PubMedCentralPubMedCrossRef Holland S, Silberstein SD, Freitag F et al (2012) Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1346–1353PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Pringsheim T, Davenport W, Mackie G et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39(2 Suppl 2):S1–S59PubMed Pringsheim T, Davenport W, Mackie G et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39(2 Suppl 2):S1–S59PubMed
22.
Zurück zum Zitat MacLennan SC, Wade FM, Forrest KM et al (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23(11):1300–1304PubMedCrossRef MacLennan SC, Wade FM, Forrest KM et al (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23(11):1300–1304PubMedCrossRef
23.
24.
Zurück zum Zitat Bruijn J, Duivenvoorden H, Passchier J et al (2010) Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 30(12):1426–1434PubMedCrossRef Bruijn J, Duivenvoorden H, Passchier J et al (2010) Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 30(12):1426–1434PubMedCrossRef
Metadaten
Titel
Riboflavin and migraine: the bridge over troubled mitochondria
verfasst von
Bruno Colombo
Lorenzo Saraceno
Giancarlo Comi
Publikationsdatum
01.05.2014
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2014
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-014-1755-z

Weitere Artikel der Sonderheft 1/2014

Neurological Sciences 1/2014 Zur Ausgabe

FICEF SYMPOSIUM - Headache in the front line: from pharmacist to general practitioner

Migraine attacks in the pharmacy: a survey in Piedmont, Italy

FICEF SYMPOSIUM - Headache in the front line: from pharmacist to general practitioner

Treatment of tension-type headache: from old myths to modern concepts

SESSION II MIGRAINE IN WOMEN

Migraine and the menopausal transition

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.